UBC finalizes first global access agreement for a new therapy

Posted on May 27, 2008. Filed under: UBC-UAEM news |

Earlier this month, UBC announced that the license agreement for Dr. Kishor Wasan’s new oral formulation of anti-fungal and anti-Leishmania drug Amphotericin B has been finalized. The agreement with iCo Therapeutics Inc. includes mechanisms to promote the availability of the drug in low- and middle-income countries, and is the first global access agreement on a new drug to be executed under UBC’s new global access principles. We at UAEM think that UBC deserves enthusiastic congratulations for its efforts on this project!

Read more in UBC’s press release.

Make a Comment

Make a Comment: ( None so far )

blockquote and a tags work here.

  • Our drugs. Our labs. Our responsibility.

    UAEM logo

    UAEM is a group of students dedicated to enhancing the impact of our universities' biomedical research on global health.

    We advocate for new medicines to be made more accessible in poor countries, and for more research on the diseases of the poor.

    Learn more about the issues here.

  • Contact us

    info@ubc-uaem.org

    Join us on:
    UBC-UAEM on Facebook Facebook
    Twitter

Liked it here?
Why not try sites on the blogroll...